University of Cleveland Medical Center
Welcome,         Profile    Billing    Logout  
 9 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zanotti, Kristine M
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NCT05113368: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
2
31
US
Regorafenib, Fulvestrant
Sarah K. Lynam MD, Bayer
Ovarian Cancer, Serous Ovarian Cancer
06/25
12/25
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Leitao, Mario M
NCT02682316: Negative Pressure Wound Therapy in Post-Operative Incision Management

Completed
3
577
US
dry gauze, The Prevena Incision Management System
Memorial Sloan Kettering Cancer Center, 3M, Miami Cancer Institute
Negative-Pressure Wound Therapy
01/24
01/24
NCT04878094: A Study of Intra-operative Imaging in Women With Ovarian Cancer

Recruiting
3
310
US
Intravenous Indocyanine Green/ICG injection, PINPOINT endoscopic fluorescence imaging system, Endoscopy
Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Ovarian Carcinoma
05/25
05/25
NCT05966584: A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Terminated
2
1
US
Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
Memorial Sloan Kettering Cancer Center, AstraZeneca, Novartis Pharmaceuticals
Breast Cancer
08/24
08/24
GROINSS-VIII, NCT05076942 / 2016-003973-16: Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

Recruiting
2
157
Europe, US
Radiotherapy combined with cisplatin, chemotherapy, Cisplatin
University Medical Center Groningen, Dutch Cancer Society, NRG Oncology
Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
01/28
01/29
NCT06127836: Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer

Recruiting
N/A
40
US
ICG guided sentinel lymph node biopsy
Memorial Sloan Kettering Cancer Center
Vulvar Cancer
11/26
11/26
NCT03517228: Pilot Trial of the Robotic Uterine Manipulator

Terminated
N/A
28
US
BAUM device
Memorial Sloan Kettering Cancer Center, Northwell Health
Gynecologic Surgery
12/23
12/23
NCT05255393: Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer

Recruiting
N/A
1026
US
Questionnaires
Memorial Sloan Kettering Cancer Center
Cervical Cancer, Vulvar Cancer
02/26
02/26
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Lim, Peter
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Withdrawn
3
320
NA
Lerociclib, Letrozole 2.5mg, Placebo
EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Carcinoma
03/24
03/25
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRĪ±) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
GOG-3088, NCT05649956: Letrozole in Uterine Leiomyosarcoma

Recruiting
2
40
US
Letrozole
GOG Foundation
Uterine Leiomyosarcoma
07/28
07/29
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Rivard, Colleen
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Rivard, Collen
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Patrick, Lauren
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29

Download Options